

ANNOUNCEMENT

12/1/93
Monsanto

Monsanto Company

The following changes are being made in the Department of Medical and Health Sciences to increase our focus on delivering key results to the operating units and the corporation. This realignment is effective December 1, 1993:

Barry R. Friedlander, M.D., will become Director, Occupational Health Management and Science. Dr. Friedlander will continue to serve as the company's focal point for establishing positions on scientific study results relative to issues of employee health.

Reporting to Dr. Friedlander will be:

John H. Baker, M.D., Director, Occupational Medicine and Chief Physician, General Offices and Chesterfield Village Teams, chair of the Substance Free Workplace Program Team, and Medical Liason for Monsanto Canada; and

Patrick R. Conner, M.D., Director, Occupational Medicine, The Chemical Group; and

Alan L. Engelberg, M.D., Director, Occupational Medicine, The Agricultural Group, NutraSweet, Asia, Latin America, and Medical Liason to Searle; and

John Jackson, M.D., Director, Medical & Health Sciences, Brussels, who will report functionally; and

Susan Wendler, Secretary.

Rebecca L. Tominack, M.D., will become Director, Medical Toxicology and Product Safety. Dr. Tominack, in her newly expanded role, will have overall responsibility for medical

-more-

RD121093-M



TOWOLDMON0008578

support for The Agricultural Group products and the corporate toxicology, epidemiology and risk assessment functions.

Reporting to Dr. Tominack will be:

James J. Collins, Ph.D., Director, Epidemiology and Health Information Services;

Mark Martens, Ph.D., Manager, Product Toxicology, currently on special assignment in St. Louis from Europe; and

Rashmi S. Nair, Ph.D., Manager, Risk Assessment.

Drs. Friedlander and Tominack will report to me.

Michael A. Pierle
Vice President, Environment, Safety
and Health

St. Louis
December 1, 1993

-oOo-